Clinical challenges on how to optimise the use of drugs beyond the label
| Autor: | S. Kruger-Peters, Yechiel A. Hekster, B. van Elk, A. Torqui, H. Leufkens |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Drug
medicine.medical_specialty Pediatrics Paediatric oncology business.industry media_common.quotation_subject Patient care Clinical Practice Invasive mycoses and compromised host [N4i 2] Promotion (rank) Age groups Family medicine medicine Dosing General Pharmacology Toxicology and Pharmaceutics business Healthcare providers media_common |
| Zdroj: | European Journal of Hospital Pharmacy, 19, 2, pp. 68 European Journal of Hospital Pharmacy, 19, 68 |
| ISSN: | 0992-4663 |
| Popis: | It is well recognised that medicinal products are often used beyond the approved labelling and patient groups for which the drug has been licensed. This is referred to as off-label use of drugs. Off-label use most often concerns the drug's indication and dosing, which occurs in various patient groups, such as children. It is a major concern that about 70% of the medicines used in the care of children are not studied, and are applied off-label in one or more of their age groups. Off-label prescribing takes place in daily clinical practice. In some cases, off-label prescribing occurs more frequently than in-label, both for new drugs and for much older drugs. Currently there is focused media attention on this issue and many articles have discussed this topic. Moreover, off-label promotion seems common practice worldwide. Healthcare providers do often not understand the legal consequences, and are not always aware of the problems involved. Off-label use of drugs should have a higher priority for health authorities, considering the impact on patient care and … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|